Drug Index


Mechanism :

Selective agonist for serotonin (5-HT1B and 5-HT1D receptors) in cranial arteries.

Indication :

  • Acute treatment of migraine with or without aura

Contraindications :

Hypersensitivity to rizatriptan or any component of the formulation; documented ischemic heart disease or other significant cardiovascular disease, history of stroke or transient ischemic attack; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; basilar or hemiplegic migraine; during or within 2 weeks of MAO inhibitors; during or within 24 hours of treatment with another 5-HT1 agonist, or an ergot-containing or ergot-type medication.

Dosing :

Use in children 6 years and above.
<40 kg:
5 mg PO as a single dose.
≥40 kg:
10 mg PO as a single dose.

Adverse Effect :

Dizziness, drowsiness, fatigue, paresthesia, nausea, xerostomia, chest pain, flushing, palpitations, weakness, jaw pain, pharyngeal edema.

Interaction :

Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators resulting in serotonin syndrome.
Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents.
Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists.
Monoamine Oxidase Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.
Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators.
Propranolol: May increase the serum concentration of Rizatriptan.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Use with caution 5 mg, repeated after 2 hours; maximum 15 mg daily

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnknown dialysability. Dose as in GFR<10 mL/min
HDUnknown dialysability. Dose as in GFR<10 mL/min
HDF/High fluxUnknown dialysability. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in GR=10–20 mL/min

Hepatic Dose :

Dose adjustment guidelines are not available, however in moderate to severe hepatic impairment the concentration can go up by 30% therefore use caution when administering, and monitor closely.
02/14/2024 21:13:06 Rizatriptan
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0